HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on UroGen Pharma (NASDAQ:URGN) with a maintained price target of $54.

May 14, 2024 | 10:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on UroGen Pharma with a $54 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. Maintaining a high price target suggests that the analyst sees significant upside potential from the current trading levels, which could positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100